Advertisement

The Role of Gemcitabine in Combined Modality Therapy

  • Jerome Landry
  • William Blackstock
  • Robert M. MacRae
  • Gary Yang
  • Hak Choy
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Gemcitabine is a novel pyrimidine nucleoside analog with a broad spectrum of clinical antitumor activity. In addition to its initial approved indication in pancreatic carcinoma, gemcitabine has been licensed for the treatment of nonsmall-cell lung cancer (NSCLC) (1). The focus of this chapter will be to examine the current preclinical and clinical evidence probing the efficacy of gemcitabine as a clinically useful radiosensitizing agent. It will begin by examining the mechanism of action of the drug itself at a cellular and molecular level.

Keywords

Pancreatic Cancer Clin Oncol Maximum Tolerate Dose Radiat Oncol Biol Phys Radiation Therapy Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Choy H. Combination chemoradiotherapy with gemcitabine: potential applications. Oncology (Huntingt) 2000; 14 (7 Suppl 4): 20–25.Google Scholar
  2. 2.
    Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22 (4 Suppl 11): 3–10.PubMedGoogle Scholar
  3. 3.
    Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48 (14): 4024–4031.PubMedGoogle Scholar
  4. 4.
    Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2’,2’-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27 (4): 258–262.PubMedCrossRefGoogle Scholar
  5. 5.
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491–498.PubMedGoogle Scholar
  6. 6.
    Grunewald R, Kantarjian H, Du M, et al. Gemcitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 1992; 10: 406–413.PubMedGoogle Scholar
  7. 7.
    Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2’,2’-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993; 45 (9): 1857–1861.PubMedCrossRefGoogle Scholar
  8. 8.
    Plunkett W, Ghandi V, Chubb S, et al. 2’,2’-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides 1989; 8: 775–785.CrossRefGoogle Scholar
  9. 9.
    Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2’,2’-difluorodeoxycytidine. Mol Pharmacol 1990; 38 (4): 567–572.PubMedGoogle Scholar
  10. 10.
    Huang P, Chubb S, Hertel LW, et al. Action of 2’,2’-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51 (22): 6110–6117.PubMedGoogle Scholar
  11. 11.
    Huang P, Plunkett W. Induction of Apoptosis by Gemcitabine. Sem Oncol 1995; 22 (4, Suppl 11): 19–25.Google Scholar
  12. 12.
    Huang P, Plunkett W. Fludarabine and gemcitabine induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181–188.PubMedCrossRefGoogle Scholar
  13. 13.
    Hui YF, Reitz J. Gemcitabine: A cytidine analogue active against solid tumors. Am JHealth-Sys Pharm 1997; 54: 162–170.Google Scholar
  14. 14.
    Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FUrefractory pancreas cancer. Ann Oncol 1996; 7 (4): 347–353.PubMedCrossRefGoogle Scholar
  15. 15.
    Bums HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (6): 2403–2413.Google Scholar
  16. 16.
    Gregoire V, Hittleman WN, Rosier JF, et al. Chemo-radiotherapy: Radiosensitizing nucleoside analogues (Review). Oncol Reports 1999; 6: 949–957.Google Scholar
  17. 17.
    Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59(1):17–114.Google Scholar
  18. 18.
    Gregoire V, Beauduin M, Bruniaux M, et al. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 1998; 73 (5): 511–520.PubMedCrossRefGoogle Scholar
  19. 19.
    Lawrence TS, Chang EY, Hahn TM, et al. Radio sensitization of pancreatic cells by 2’,2’-difluro-2’deoxycytidine. Int J Rad Onc Biol Phys 1996; 34: 867–872.CrossRefGoogle Scholar
  20. 20.
    Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2’,2’-difluoro-2’-deoxycytidine (Gemcitabine). Clin Cancer Res 1997; 3 (5): 777–782.PubMedGoogle Scholar
  21. 21.
    Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2’,2’-difluoro-2’-deoxycytidine) within the cell cycle in vitro. IntJRadiat Oncol Biol Phys 1998; 41 (4): 875–882.CrossRefGoogle Scholar
  22. 22.
    Mose S, Karapetian M, Juling-Pohlit L, et al. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res 2000; 20 (1A): 401–405.PubMedGoogle Scholar
  23. 23.
    Rosier JF, Beauduin M, Bruniaux M, et al. The effect of 2’-2’ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol 1999; 75 (2): 245–251.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang XL, Yang SJ, Ashamalla H, et al. Gemcitabine induced radio sensitization of human breast cancer cells. Pro Am Soc Clin Oncol 1998; 17:abstract 1732.Google Scholar
  25. 25.
    Ostruszka Li, Shewach DS. Gemcitabine and radio sensitization in two glioblastoma cells lines. Proc Amer Soc Cancer Res 1998; 39:abstract 2599.Google Scholar
  26. 26.
    Rockwell S, Grindey GB. Effect of 2’-2’ difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 1992; 4: 151–155.PubMedGoogle Scholar
  27. 27.
    Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2’-2’ difluorodeoxycytidine and Radiation Sensitization of Human Colon carcinoma cells. Cancer Res 1994; 54: 3218–3223.PubMedGoogle Scholar
  28. 28.
    Tannock IF, Hill RP. The Basic Science of Oncology 3rd Edition. McGraw-Hill. St. Louis. 1998, pp. 295–419.Google Scholar
  29. 29.
    Chen M, Hough AM, Lawrence TS. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 2000; 45 (5): 369–374.PubMedCrossRefGoogle Scholar
  30. 30.
    Milas I, Milas MM, Mason KA. Combination of Taxanes with radiation: preclinical studies. Sem Rad Oncol 1999; 9 (2, Suppl 1): 12–26.Google Scholar
  31. 31.
    Joschko MA, Webster LK, Groves J, et al. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Investig 1997; 5 (2): 62–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once-vs. twice-weekly 2’2’-difluoro-2’-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000; 47 (3): 785–791.PubMedCrossRefGoogle Scholar
  33. 33.
    Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59 (1): 107–114.PubMedGoogle Scholar
  34. 34.
    Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999; 44 (5): 1125–1135.PubMedCrossRefGoogle Scholar
  35. 35.
    Gregoire V, Cvilic S, Beauduin M, De Coster B, Gueulette J, Octave-Prignot M, Scalliet P. Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice. Radiat Res 1999; 151 (6): 747–749.PubMedCrossRefGoogle Scholar
  36. 36.
    Attar EC, Ervin T, Janicek M, et al. Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol 2000; 18 (3): 697–698.PubMedGoogle Scholar
  37. 37.
    Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80 (2): 286–291.PubMedCrossRefGoogle Scholar
  38. 38.
    Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18 (3): 693–694.PubMedGoogle Scholar
  39. 39.
    Castellano D, Hitt R, Cortes-Funes H, Romero A, Rodriguez-Peralto JL. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18 (3): 695–696.PubMedGoogle Scholar
  40. 40.
    Scalliet P, Goor C, Galdermans D, et al. Gemzar (Gemcitabine) with thoracic radiotherapy-A phase II pilot study in chemonaive patients with advanced nonsmall-cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 1998; 17:abstract 1923.Google Scholar
  41. 41.
    Vokes EE, Gregor A, Turrisi AT. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 1998; 25 (4 Suppl 9): 66–69.PubMedGoogle Scholar
  42. 42.
    Gregor A. Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin Oncol 1997; 24(3 Suppl 8):S839–S841.Google Scholar
  43. 43.
    Vokes EE, Leopold KA, Herndon JE, et al. CALGB Study 9431: A randomized phase study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer. Lung Cancer 2000; 29(S1):49(abstract 158).CrossRefGoogle Scholar
  44. 44.
    Groen H, Gregor A, van Putten J, et al. Phase I study of gemcitabine(G) and high dose thoracic radiation (RT) in Stage III Non-Small Lung Cancer. Pro Am Soc Clin Oncol 2000; 19:abstract 2123.Google Scholar
  45. 45.
    Goss G, Lochrin C, Perry G, et al. A phase I study of gemcitabine and Cisplatin with concurrent curative irradiation in Stage III Non-small cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 1999; 18:abstract 1986.Google Scholar
  46. 46.
    Fossella FV, Zinner RG, Komaki R, et al. Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin: A phase I trial for patients with stage III non-small cell lung cancer. Lung Cancer 2000; 29 (Suppl 1): 111 (abstract 368).CrossRefGoogle Scholar
  47. 47.
    Blackstock AW, Lesser G, Tucker G, et al. Twice-weekly gemcitabine and concurrent thoracic radiotherapy-a phase I/II study in patients with advanced nonsmall-cell lung cancer. Pro Am Soc Clin Oncol 2000; 19: 47a (abstract 1846).Google Scholar
  48. 48.
    Varveris C, Lyraraki E, Kachris S, et al. Phase I/II study of gemcitabine combined to cisplatin weekly with concurrent thoracic MV-radiotherapy for patients with stage III A/B nonsmall-cell lung cancer. Proc Am Soc Clin Oncol 2000; 19: 537a (abstract 2116).Google Scholar
  49. 49.
    Gonzales E, Sanchez-Rovira P, Jaen A, Nobody A. Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC. Eur J Can 1999; 35 (Suppl 4): A1054.Google Scholar
  50. 50.
    Blackstock AW, Lightfoot H, Kwock L, Leadon SA, Hess S, Tepper JE. Gemcitabine: in vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dosing schedule-pre-clinical observations relevant to gemcitabine clinical trials. Int J Radiat Oncol Bio Phys 1997; 39: 205.CrossRefGoogle Scholar
  51. 51.
    Jaremtchuk V, Zarba JJ, Keropian M, Castagnino R, Gonzalez Jazey P. Low dose gemcitabine plus concurrent therapy with or without amifostine in locally advanced head and neck cancer. Proc of 1 l th NCI-EORTC-ACCR Symposium on New Drugs in Cancer Therapy, November 7–10,2000 Proc ASCO 2000; 19: 424a (abstract 1674).Google Scholar
  52. 52.
    McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994; 29: 747–754.PubMedCrossRefGoogle Scholar
  53. 53.
    Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998; 9: 505–509.PubMedCrossRefGoogle Scholar
  54. 54.
    Wildfang I, Raub M, Guner SA, Rades D, Karstens JH. Low-dose gemcitabine with radiotherapy in advanced head and neck and thyroid cancer. J Can Res Clin Oncol 2000; 126:R:40.Google Scholar
  55. 55.
    Eisbruch A, Shewach DS, Bradford CR, et al. Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study. J Clin Oncol 2001; 19: 792–799.PubMedGoogle Scholar
  56. 56.
    Benasso M, Merlano M, Corvo R, Sanguineti G, Numico G, Di Costanzo G, Ricci I, Rosso R. Alternating/concomitant gemcitabine (GEM), cisplatin (CDDP) and radiotherapy (RT) in advanced squamous cell carcinoma of the head and neck (SCC-HN). Proc ASCO 1998; 17: 403a (abstract 1552).Google Scholar
  57. 57.
    Humerickhouse R, Haraf D, Brockstein B, Gordon G, Dolan ME, Mansur D, Elahi R. Gemcitabine, 5-fluorouracil, and paclitaxel with concomitant radiotherapy in recurrent or advanced head and neck cancer. Can Invest 2000; 18: 32–33.CrossRefGoogle Scholar
  58. 58.
    Wilkowski R, Heinemann V, Rau H, et al. Radiochemotherapy including gemcitabine and 5-FU for treatment of locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 276a.Google Scholar
  59. 59.
    Kudromoti M, Regine W, John W, et al. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: A phase I/II study. Proc Am Soc Clin Oncol 1999; 18: 242a.Google Scholar
  60. 60.
    Friedman NS, Brenner MJ, Linder JA, et al. Adjuvant radiation and continuous 5-FU followed by gemcitabine as adjuvant treatment for resected pancreatic cancer. Proc Am Soc Clin Oncol 1999; 18: 283a.Google Scholar
  61. 61.
    Hoffman JP, McGinn CJ, Szarka C, et al. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 283a.Google Scholar
  62. 62.
    McGinn CJ, Smith DC, Szarka CE, et al. A phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17: 264a.Google Scholar
  63. 63.
    Safar AM, Altamiro PS, Recht A, et al. Phase I trial of gemcitabine, cisplatin and external beam radiation therapy for pancreatic cancer. Proc Am Soc Clin Oncol 1999; 18: 227a.Google Scholar
  64. 64.
    Landry JC, Harris W Yang GY, et al. Neoadjuvant treatment with GEM, cisplatin, 5-FU and accelerated hyperfractionated radiation therapy in advanced GI malignancy. Radiology 2000; 217: 147.Google Scholar
  65. 65.
    Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. JCO 1999; 17: 2208–2212.Google Scholar
  66. 66.
    Sandler AB, Kindler HL, Einhorn LH, et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 2000; 11: 1161–1164.PubMedCrossRefGoogle Scholar
  67. 67.
    Abbruzzese JL, Pazdur R, Ajani J, et al. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 456.Google Scholar
  68. 68.
    Mani S, et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer. Invest New Drugs 1998; 16: 275.PubMedCrossRefGoogle Scholar
  69. 69.
    Fink U, Molle B, Daschner H, et al. Phase II study of gemcitabine in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992; 11: 173.Google Scholar
  70. 70.
    Christman K, Kelsen D, Saltz L, et al. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73: 5–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Sessa C, Aamdal S, Wolff I, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trial group. Ann Oncol 1994; 5: 471–472.PubMedGoogle Scholar
  72. 72.
    Dragovich T, Ramanathan, Remick S, et al. Phase II trial of a weekly 150-minute gemcitabine infusion in patients with biliary tree carcinomas. Proc Am Soc Clin Oncol 2000; 19: 296a.Google Scholar
  73. 73.
    Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89: 750–756.PubMedCrossRefGoogle Scholar
  74. 74.
    Weissmann A, Ludwig H. Intrarterial gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma. Proc Am Soc Clin Oncol 1999; 18: 305a.Google Scholar
  75. 75.
    Fuloria JF, Parikh PM, Prabhakaran PS, et al. A multicenter, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2000; 19: 29.Google Scholar
  76. 76.
    Pattaranutaporn P, Thirapakawong C, Chansilpa Y, et al. Study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Pro Am Soc Clin Oncol 2000; 19: 390a (abstract 1545).Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Jerome Landry
  • William Blackstock
  • Robert M. MacRae
  • Gary Yang
  • Hak Choy

There are no affiliations available

Personalised recommendations